190 related articles for article (PubMed ID: 35399606)
1. Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
Bates EA; Davies JA; Váňová J; Nestić D; Meniel VS; Koushyar S; Cunliffe TG; Mundy RM; Moses E; Uusi-Kerttula HK; Baker AT; Cole DK; Majhen D; Rizkallah PJ; Phesse T; Chester JD; Parker AL
Mol Ther Oncolytics; 2022 Jun; 25():43-56. PubMed ID: 35399606
[TBL] [Abstract][Full Text] [Related]
2. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.
Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL
Oncotarget; 2016 May; 7(19):27926-37. PubMed ID: 27056886
[TBL] [Abstract][Full Text] [Related]
3. Ad5
Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL
Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908
[No Abstract] [Full Text] [Related]
4. Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5
Davies JA; Marlow G; Uusi-Kerttula HK; Seaton G; Piggott L; Badder LM; Clarkson RWE; Chester JD; Parker AL
Viruses; 2021 May; 13(5):. PubMed ID: 34066836
[TBL] [Abstract][Full Text] [Related]
5. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.
Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ
J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326
[TBL] [Abstract][Full Text] [Related]
6. The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism.
Baker AT; Davies JA; Bates EA; Moses E; Mundy RM; Marlow G; Cole DK; Bliss CM; Rizkallah PJ; Parker AL
J Virol; 2021 Jan; 95(4):. PubMed ID: 33268514
[TBL] [Abstract][Full Text] [Related]
7. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.
Coughlan L; Uusi-Kerttula H; Ma J; Degg BP; Parker AL; Baker AH
Hum Gene Ther; 2014 Apr; 25(4):385-94. PubMed ID: 24617540
[TBL] [Abstract][Full Text] [Related]
8. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.
Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells.
Phanthaphol N; Somboonpatarakun C; Suwanchiwasiri K; Chieochansin T; Sujjitjoon J; Wongkham S; Maher J; Junking M; Yenchitsomanus PT
Front Oncol; 2021; 11():657868. PubMed ID: 33763382
[TBL] [Abstract][Full Text] [Related]
10. Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction
Lopez-Gordo E; Doszpoly A; Duffy MR; Coughlan L; Bradshaw AC; White KM; Denby L; Nicklin SA; Baker AH
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381574
[TBL] [Abstract][Full Text] [Related]
11. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.
Stepanenko AA; Chekhonin VP
Virus Res; 2018 Sep; 257():40-51. PubMed ID: 30125593
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy.
Romanenko M; Osipov I; Netesov SV; Davydova J
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683934
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic.
Wang X; Kerkmann L; Hetzel M; Windmann S; Trilling M; Zhang W; Ehrhardt A; Bayer W
J Virol; 2022 Nov; 96(22):e0113322. PubMed ID: 36342295
[TBL] [Abstract][Full Text] [Related]
14. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.
Hulin-Curtis SL; Davies JA; Nestić D; Bates EA; Baker AT; Cunliffe TG; Majhen D; Chester JD; Parker AL
Cancer Gene Ther; 2020 Nov; 27(10-11):785-798. PubMed ID: 31902944
[TBL] [Abstract][Full Text] [Related]
15. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
Biomed Pharmacother; 2024 May; 175():116718. PubMed ID: 38744221
[TBL] [Abstract][Full Text] [Related]
16. Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.
Bots STF; Kemp V; Cramer SJ; van den Wollenberg DJM; Hornsveld M; Lamfers MLM; van der Pluijm G; Hoeben RC
Hum Gene Ther; 2022 Mar; 33(5-6):275-289. PubMed ID: 34861769
[TBL] [Abstract][Full Text] [Related]
17. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM; Parente-Pereira AC; Zabinski T; Davies DM; Petrovic RMG; Kao YV; Saxena SA; Romain A; Costa-Guerra JA; Violette S; Itamochi H; Ghaem-Maghami S; Vallath S; Marshall JF; Maher J
Mol Ther; 2017 Jan; 25(1):259-273. PubMed ID: 28129120
[TBL] [Abstract][Full Text] [Related]
18. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations.
Murakami M; Ugai H; Wang M; Belousova N; Dent P; Fisher PB; Glasgow JN; Everts M; Curiel DT
Virology; 2010 Nov; 407(2):196-205. PubMed ID: 20828776
[TBL] [Abstract][Full Text] [Related]
19. Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.
Ballmann MZ; Raus S; Engelhart R; Kaján GL; Beqqali A; Hadoke PWF; van der Zalm C; Papp T; John L; Khan S; Boedhoe S; Danskog K; Frängsmyr L; Custers J; Bakker WAM; van der Schaar HM; Arnberg N; Lemckert AAC; Havenga M; Baker AH
J Virol; 2021 Oct; 95(22):e0038721. PubMed ID: 34469243
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Uusi-Kerttula H; Legut M; Davies J; Jones R; Hudson E; Hanna L; Stanton RJ; Chester JD; Parker AL
Hum Gene Ther; 2015 May; 26(5):320-9. PubMed ID: 25919378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
